Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Covered in this story
What has happened since
- Post Holdings is up 7.3% since this was published, 14 days ago.
- Regeneron Pharmaceuticals is up 7.3% since this was published, 14 days ago.
- Associated Bancorp is up 0.6% since this was published, 14 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $POST yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Post Holdings →Dalsna Finance is currently tracking 9 stories mentioning Post Holdings, the earliest published 19 May 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.